We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genome of the Lone Star Virus Quickly Unmasked by Ultradeep Gene Sequencing

By LabMedica International staff writers
Posted on 13 May 2013
Print article
Image: Senior author Dr. Charles Chiu (Photo courtesy of Susan Merrell, University of California, San Francisco).
Image: Senior author Dr. Charles Chiu (Photo courtesy of Susan Merrell, University of California, San Francisco).
Virologist have used next generation "ultradeep" gene sequencing and analysis coupled with de novo synthesis of the viral genome to assign a unique example of the Lone Star virus (LSV) to the bunyavirus family of tick-borne viruses, which includes several human pathogens.

Depth in DNA sequencing refers to the number of times a nucleotide is read during the sequencing process. Deep sequencing indicates that the coverage, or depth, of the process is many times larger than the length of the sequence under study. The term "deep" has been used for a wide range of depths (at least 7 times), and the newer term "ultradeep" has appeared in the scientific literature to refer to even higher coverage (at least 100 times). Even though the sequencing accuracy for each individual nucleotide is very high, the very large number of nucleotides in the genome means that if an individual genome is only sequenced once, there will be a significant number of sequencing errors. Furthermore, rare single-nucleotide polymorphisms (SNPs) are common. Hence to distinguish between sequencing errors and true SNPs, it is necessary to increase the sequencing accuracy even further by sequencing individual genomes a large number of times.

In a paper published in the April 29, 2013, online edition of the journal PLOS ONE investigators at the University of California, San Francisco (USA) reported results from ultradeep sequencing that covered the LSV genome more than 1,000 times. The gene sequencing technology used for this study allowed complete reconstruction of the viral genome in less than 24 hours—significantly faster than conventional sequencing techniques, which can take days to weeks.

The LSV sample had originally been isolated from the lone star tick Amblyomma americanum. The LSV isolate was able to infect both human (HeLa) and monkey (Vero) cells. Cytopathic effects were seen within 72 hours in both cell lines; vacuolization was observed in infected Vero, but not HeLa, cells.

Viral culture supernatants were examined by unbiased deep sequencing and analysis using an in-house developed rapid computational pipeline for viral discovery, which definitively identified LSV as a Phlebovirus. De novo assembly of the full genome revealed that LSV was highly divergent, sharing less than 61% overall amino acid identity with any other bunyaviruses. Despite this sequence diversity, LSV was found by phylogenetic analysis to be part of a well-supported clade that includes members of the Bhanja group viruses, which are most closely related to severe fever with thrombocytopenia syndrome virus (SFTSV) in China and heartland virus (HRTV) in the USA.

“We did not show that Lone Star virus causes disease in humans, although the laboratory and sequencing data suggest that this is a distinct possibility,” said senior author Dr. Charles Chiu, assistant professor of laboratory medicine at the University of California, San Francisco.

“Nature is continually throwing us curveballs,” said Dr. Chiu. “We will likely always be faced with the threat of novel outbreak viruses originating in animals or insects. It will be extremely important to identify and characterize those viruses as quickly as possible – to get a head start on the development of diagnostic assays for surveillance and drugs, or vaccines for treatment – before they have a chance to really spread. By the time SARS was identified and sequenced using conventional methods, more than a week of time had been lost. That kind of delay could be quite risky in a virus that spreads rapidly in human populations.”

Related Links:
University of California, San Francisco


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.